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Introduction 
 
Taste assessment has become an important element of pharmaceutical drug development 
especially since paediatric regulations have been enforced in the US and EU. Evaluating the 
taste of new active pharmaceutical ingredients (APIs) is therefore essential to put in place 
adequate taste-masking techniques which will lead to appropriate palatable formulation.  
Thus, there is an urgent need to develop and optimise taste assessment methods that can be 
used at different stages of the drug development process.  
 
Purpose 
 
To assess the validity of the in vivo rat brief-access taste aversion (BATA) model as a 
screening tool for taste assessment of APIs and to compare the rat panel results with the 
human taste results.   
 
Materials and Methods 
 
Five bitter model drug substances have been selected to verify the model. The taste of 6 
concentrations of quinine hydrochloride dihydrate (QHD), caffeine citrate (CC), diclofenac 
sodium (DS), sildenafil citrate (SC) and paracetamol (PAR) in water was assessed in ten male 
Sprague-Dawley rats with the BATA model (Soto et al. 2015). Taste was assessed using the 
lickometer “Davis Rig MS-160”, an apparatus that electronically records the number of licks 
that mildly water-deprived rats do to different API samples presented randomly. The taste of 
4 concentrations of these same drugs was also assessed by a human taste panel conducted in 
20 healthy young volunteers using the “swirl and spit” method. [UCL REC 4612/005]: 10 mL 
of each sample were gargled for 5 s and then expectorated. The volunteers rated the taste 
intensity on a Visual Analogue Scale (VAS) using the software Qualtrics.  
 
Results 
 
The rat data showed the same rank order of bitterness prediction (IC50) as the human panel 
for all the drugs. Despite a slight shift between rats’ and humans’ responses, a good 
correlation (R
2
= 0.9968) was observed. Furthermore, a lower variability was observed in the 
rat panel.  
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Conclusions 
 
The taste of five different API’s has been tested using two different methods, the rat and the 
human taste panels. An excellent correlation between the two methods was obtained which is 
a further milestone towards the validation of the animal model as an in vivo taste assessment 
tool. 
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